Cochrane · systematic review · CD007694
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
O'Shea, O, Stovold, E, Cates, CJ · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 5 · 27.8%Very low 3 · 16.7%Low 7 · 38.9%Moderate 3 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsAdults: formoterol/ICS compared to salmeterol/ICS for chronic asthma: all‐cause mortality
Population: adults, chronic asthma: all‐cause mortality
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality ‐ formoterol/budesonide vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 1.03 [0.06, 16.44] | 7 studies · 5935 participants | Low Downgraded: imprecision |
All‐cause mortality ‐ formoterol/beclomethasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | no estimate extracted | 4 studies · 1257 participants | Ungraded |
All‐cause mortality ‐ formoterol/mometasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 4.46 [0.23, 85.4] | 2 studies · 1126 participants | Low Downgraded: imprecision |
All‐cause mortality ‐ formoterol/fluticasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 7.39 [0.15, 372.38] | 2 studies · 270 participants | Low Downgraded: imprecision |
All‐cause mortality formoterol/budesonide vs salmeterol/budesonide Adults: formoterol/ICS vs salmeterol/ICS | no estimate extracted | 1 study · 229 participants | Ungraded |
Adults: formoterol/ICS compared to salmeterol/ICS for chronic asthma: all‐cause serious adverse events
Population: adults, chronic asthma: serious adverse events
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 1.14 [0.82, 1.59] | 7 studies · 5935 participants | Moderate |
All‐cause non‐fatal serious adverse events ‐ formoterol/beclomethasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 0.94 [0.43, 2.08] | 6 studies · 1941 participants | Moderate |
All‐cause non‐fatal serious adverse events ‐ formoterol/mometasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 1.02 [0.47, 2.2] | 2 studies · 1126 participants | Moderate |
All‐cause non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 0.05 [0, 3.1] | 2 studies · 293 participants | Low |
All‐cause non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide Adults: formoterol/ICS vs salmeterol/ICS | OR 7.45 [0.15, 375.68] | 1 study · 229 participants | Low |
Adults: formoterol/ICS compared to salmeterol/ICS for chronic asthma: asthma‐related serious adverse events
Population: adults, chronic asthma: asthma‐related serious adverse events
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Asthma‐related non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 0.69 [0.37, 1.26] | 7 studies · 5935 participants | Low |
Asthma‐related non‐fatal serious adverse events ‐ formoterol/beclomethasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 1.01 [0.06, 16.24] | 5 studies · 1510 participants | Very low |
Asthma related non‐fatal serious adverse events ‐ formoterol/mometasone v's salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 7 [0.14, 353.37] | 1 study · 722 participants | Very low |
Asthma‐related non‐fatal serious adverse events ‐ formoterol/fluticasone vs salmeterol/fluticasone Adults: formoterol/ICS vs salmeterol/ICS | OR 0.05 [0, 3.1] | 2 studies · 293 participants | Very low |
Asthma‐related non‐fatal serious adverse events ‐ formoterol/budesonide vs salmeterol/budesonide Adults: formoterol/ICS vs salmeterol/ICS | no estimate extracted | 1 study · 229 participants | Ungraded |
Children: formoterol/fluticasone compared to salmeterol/fluticasone for chronic asthma: serious adverse events
Population: children, chronic asthma: serious adverse events
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Children: formoterol/fluticasone vs salmeterol/fluticasone | no estimate extracted | 2 studies · 548 participants | Ungraded |
All‐cause non‐fatal serious adverse events Children: formoterol/fluticasone vs salmeterol/fluticasone | OR 2.72 [0.38, 19.46] | 2 studies · 548 participants | Low Downgraded: imprecision |
Asthma‐related non‐fatal serious adverse events Children: formoterol/fluticasone vs salmeterol/fluticasone | no estimate extracted | 2 studies · 548 participants | Ungraded |